FDAsafety guidance54% confidence
FDA AP — LENALIDOMIDE (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin.
Regulatory Analysis
Application ANDA209348. Sponsor: DR REDDYS. Submission status: AP. Submission type: SUPPL. Active ingredients: LENALIDOMIDE.
Supporting Context
- Therapeutic area
- Oncology · Immunomodulator
- Sub-indication
- General
Related signal: Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval